Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 6 results:
[ Author(Asc)] Title Type Year
Filters: Author is Filion, K. B.  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
F
K. B. Filion, Chateau, D., Targownik, L. E., Gershon, A., Durand, M., Tamim, H., Teare, G. F., Ravani, P., Ernst, P., and Dormuth, C. R., Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis, Gut, vol. 63, pp. 552-8, 2014.
K. B. Filion, Delaney, J. A., Brophy, J. M., Ernst, P., and Suissa, S., The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database, Pharmacoepidemiol Drug Saf, vol. 16, pp. 1-4, 2007.
K. B. Filion, Joseph, L., Boivin, J. F., Suissa, S., and Brophy, J. M., Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis, Pharmacoepidemiol Drug Saf, vol. 18, pp. 973-6, 2009.
K. B. Filion, Joseph, L., Boivin, J. F., Suissa, S., and Brophy, J. M., Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus, Pharmacoepidemiol Drug Saf, vol. 20, pp. 785-96, 2011.
K. B. Filion, Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., Udell, J. A., and Ernst, P., A Multicenter Observational Study of Incretin-based Drugs and Heart Failure, N Engl J Med, vol. 374, pp. 1145-54, 2016.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study, Br J Clin Pharmacol, 2019.
[Page last reviewed 6 December 2019]